Memorandum for DHA Staff - Military Medical Treatment Facilities to Implement Updated DHA COVID-19 Medical Coding Policy

Handout that accompanies the DHA Policy Memorandum about the COVID-19 Medical Coding Policy; updated to include the 2021 procedure and diagnosis codes for COVID-19, including the new vaccination and treatment codes.

This memorandum provides supplemental guidance on the provision of coronavirus disease 2019 (COVID-19) vaccines, in accordance with reference (a). The Defense Health Agency (DHA) is the lead coordinating DOD Component for executing this guidance, in coordination with the Military Departments and other DOD Components as appropriate.

This memorandum provides guidance for a COVID-19 laboratory pre-testing questionnaire that will be mandatory for all Active Duty Service members and encouraged for all other DOD beneficiaries treated at military medical treatment facilities.

Upon transfer, the Director, DHA, will assume responsibility for ensuring all Armed Services Blood Program (ASBP) activities are FDA-compliant.

On July 9, 2014, the Deputy Secretary of Defense approved the realignment of medical Department of Defense (DoD) Executive Agent (EA) organizations to the Defense Health Agency (DHA), including the Armed Services Blood Program Office (ASBPO) and DoD Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome Prevention Program (DHAPP).

This guidance contains information about the potential for transfusion-transmitted Zika infection; recommends facilitating donor self-deferral of 28 days after travel to Mexico, the Caribbean, Central America and South America.

Transition of Executive Agent Responsibilities to the DHA